Impact of comprehensive molecular testing to reduce antibiotic use in community-acquired pneumonia (RADICAP): a randomised, controlled, phase IV clinical trial protocol지역사회획득 폐렴(RADICAP)에서 항생제 사용을 줄이기 위한 포괄적인 분자 테스트의 영향: 무작위, 통제된, IV상 임상 시험 프로토콜Article Published on 2020-08-202022-09-11 Journal: BMJ Open [Category] MERS, 임상, 진단, [키워드] 1:1 48 hour 48 hours Admission adverse events antibiotic Antibiotic therapy Antibiotic treatment antibiotic use Antibiotics antimicrobial resistance assigned both group both groups causative agent clinical trial ClinicalTrials community-acquired pneumonia De-escalation death Device Diagnosis diagnostic Diagnostic microbiology effective eligible Endpoint Escalation Ethical approval Ethics ethics committee Health health problem hospital hospitalised Hypothesis Immunosuppressed Impact include intensive care intensive care unit admission International intravenous mechanical ventilation Medical devices Medicine molecular molecular diagnostics null hypothesis Open-label parallel group Patient patients Pneumonia primary endpoint Probability protocol randomisation randomised Randomly readmission receive reduce reducing registration number respiratory respiratory infections Result resulting secondary Secondary endpoints Side effects Spanish stability subject [DOI] 10.1136/bmjopen-2020-038957 PMC 바로가기 [Article Type] Article
Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trialLetter Published on 2020-07-292022-10-29 Journal: Trials [Category] COVID-19, SARS, [키워드] 1:1 acute respiratory syndrome Adults adverse event antiretroviral Antiviral Arm Barcelona blinded Blood Breastfeeding Chloroquine condition confirmed case confirmed COVID-19 case Contact Control control group Controlled clinical trial coronavirus coronavirus disease Corticosteroid COVID-19 declining defined develop disease dissemination double-blind double-blinded Efficacy element eligibility Epidemic equipment evaluate Follow-up group healthcare worker Healthcare workers high risk hospital Hydroxychloroquine hydroxychloroquine treatment identify incidence Infection Intervention intervention group investigator marker multicentre National number Nurse objective Occurrence Older outcome participant Participants PCR physical Placebo placebo tablet polymerase chain positive PCR PPE pre-exposure predict predictor Pregnancy primary endpoint Prophylaxis protocol random randomisation randomised randomised controlled trial Randomized Randomized controlled trial Rapid diagnostic test RDT reached receive recruited reducing Registered Repository Research risk Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR Secondary endpoints Seroconversion serological serology serum sample Spain Spanish Standard of care status Study protocol Symptom Tablet the placebo group the SARS-CoV-2 Treatment Trial website with COVID-19 [DOI] 10.1186/s13063-020-04621-7 PMC 바로가기 [Article Type] Letter
Neurological Comorbidity Is a Predictor of Death in Covid-19 Disease: A Cohort Study on 576 PatientsNeurology Published on 2020-07-072022-11-01 Journal: Frontiers in Neurology [Category] COVID-19, [키워드] Admission all-cause mortality analyzed association Care clinical symptom clinical variables CND cohort study Comorbidity condition Coronavirus disease 2019 death defined Disabled disease evaluated explained female had more hospital Hospitalized hospitalized patient immune response In-hospital in-hospital mortality independent INR laboratory abnormalities laboratory abnormality laboratory parameter log rank test Mortality Nervous system diseases neurological Neurological disorder Older outcome Patient patients Presence primary endpoint procalcitonin Prognosis risk factor Risk factors SARS-CoV-2 Secondary endpoints severity stroke Support Vascular Ventilation [DOI] 10.3389/fneur.2020.00781 PMC 바로가기 [Article Type] Neurology
Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial경증/중등도의 COVID-19 성인 환자에 대한 로피나비르/리토나비르 또는 아르비돌의 효능 및 안전성: 탐색적 무작위 대조 시험Randomized Controlled Trial Published on 2020-05-192022-09-14 Journal: Med (New York, N.Y.) [Category] SARS, 임상, 진단, 치료제, [키워드] adverse event affected antiviral medication approved Arbidol assigned benefit caused Characteristics Chest computed tomography clinical Clinical outcome clinical status clinician comparable Context control group Controlled Controlled trial coronavirus SARS-CoV-2 cough COVID-19 COVID-19 pandemic Deterioration drug effective Efficacy Efficacy and safety enrolled exploratory finding follow-up period funding global pandemic group Guangzhou HIV-1 IMPROVE Influenza Lopinavir/ritonavir Mild moderate Moderate COVID-19 monotherapy no difference novel coronavirus SARS-CoV-2 occurred pathogen Patient patients hospitalized primary endpoint Randomized Randomly receive Respiratory illness responsible Safety SARS-CoV-2 SARS-CoV-2 nucleic acid Scientific community Secondary endpoints Significance standard care supported supportive care tested the disease therapy three group Treatment university virus [DOI] 10.1016/j.medj.2020.04.001 PMC 바로가기 [Article Type] Randomized Controlled Trial